Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products

Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.